Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Braze Inc (BRZE) vs Cassava Sciences Inc (FLNA) Price & Performance

Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Braze Inc vs Cassava Sciences Inc — how do they compare? Braze Inc trades at $27.59 (market cap $3.18B), while Cassava Sciences Inc trades at $0.94 (market cap $47.75M). The key difference: Braze Inc is far larger — about 66.6× Cassava Sciences Inc's market cap, and Braze Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

BRZEFLNA
Market Cap
$3.18B$47.75M
Sector
TechnologyHealth
52-Week High
$36.19$4.64
52-Week Low
$15.79$0.87
Enterprise Value
$2.87B-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Braze Inc

Braze (BRZE) trades at $27.71, down 3.62% today, with strong analyst support (96% buy ratings) and a $34.78 consensus price target. The stock shows bullish technical momentum despite recent earnings misses, with revenue growing 30% year-over-year to $593M in 2025. Recent news highlights insider selling and AI-driven sector recovery, while the company maintains robust gross margins of 66.5% but remains unprofitable with a -15.5% net margin.

The outlook remains positive based on accelerating revenue growth and strong institutional backing, though profitability challenges and recent insider selling present near-term risks. With technical indicators showing bullish momentum and the stock trading below analyst targets, BRZE offers growth potential but requires monitoring of execution on path to profitability.

Cassava Sciences Inc

FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.

The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.

Returns comparison

Trailing returns across standard periods

About Braze Inc

Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.

Read more on BRZE

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA